Seoul
Chief MD, Gangnam
Duk-ha Kim
The trust our patients have placed in this clinic was built on conviction and principle. We intend to hold to both, unchanged, through the next hundred years.
FILLMED NCTF injectable formulation guide
NCTF Mesotherapy
NCTF Mesotherapy is treatment with one specific product line — FILLMED Laboratoires’ NCTF — rather than a general injectable category. The manufacturer describes it as a 60-ingredient combination of vitamins, amino acids, minerals and hyaluronic acid, which is a composition disclosure rather than a claim that each ingredient works. The one product-specific clinical trial identified tested NCTF 135HA added to picosecond laser treatment for melasma, compared with laser alone — a combination study, not a test of this product by itself.
- Manufacturer
- FILLMED Laboratoires (formerly Filorga’s professional-use line); the NCTF formulation was developed in 1978
- Composition
- Manufacturer states 60 active ingredients — vitamins, amino acids, minerals and hyaluronic acid in one formulation
- Certification
- CE marking and MDR certification, dated 2025-02
- Only product-specific trial identified
- Melasma RCT: NCTF 135HA + picosecond laser (n=19) vs laser alone (n=12), single-centre Moscow, 2-month follow-up, recurrence 5.3% vs 25% (p<0.05)
What is NCTF Mesotherapy?
NCTF Mesotherapy is the common name for treatment with FILLMED Laboratoires’ NCTF product line, delivered by injection into the skin. It is a specific manufacturer’s formulation rather than a defined treatment category, so what applies to it is what the manufacturer states about this product and what one identified clinical trial tested on it — not general claims about mesotherapy or skin boosters as a category.
Sources: FILLMED Laboratoires — NCTF product page, composition, certification and contraindications
Who manufactures the product used in this treatment?
The manufacturer is FILLMED Laboratoires, which the company describes as formerly Filorga’s professional-use line. The NCTF formulation itself was developed in 1978. A consent form or product box may read either Filorga or FILLMED depending on when it was sourced, so confirming the manufacturer name printed on the box you are shown is a reasonable consultation question.
Sources: FILLMED Laboratoires — NCTF product page, composition, certification and contraindications
What is actually in the syringe?
The manufacturer states the product contains 60 active ingredients, described as a combination including vitamins, amino acids, minerals and hyaluronic acid. That is a composition disclosure — a list of what the product is made of — not a statement about what each of those sixty components has been shown to do on its own or in combination.
Sources: FILLMED Laboratoires — NCTF product page, composition, certification and contraindications
Does a 60-ingredient list mean each ingredient’s effect is proven?
No. A product formulated from 60 ingredients tells you the formulation is complex; it does not tell you that each ingredient’s individual contribution has been separately tested, or that the combination has been shown to outperform a simpler product. Reading a long ingredient list as evidence of effect, rather than as a list of contents, is the substitution to watch for when comparing this treatment to others.
Sources: FILLMED Laboratoires — NCTF product page, composition, certification and contraindications
What does the CE marking and MDR certification cover?
The manufacturer states the product carries CE marking and MDR certification dated 2025-02. That is a marking of conformity with the EU’s medical device regulatory framework — manufacturing, quality and safety requirements for the device — rather than a certification of any specific cosmetic outcome for any specific skin concern.
Sources: FILLMED Laboratoires — NCTF product page, composition, certification and contraindications
What does this certification not tell you?
It does not tell you what the product does for melasma, hydration or any other concern — that question is answered, if at all, by clinical trial evidence rather than by a regulatory conformity mark. The only outcome evidence identified on this page is the melasma trial described below, and it applies to one combination protocol, not to the product’s certification status.
Who does the manufacturer say should not receive this treatment?
The manufacturer lists contraindications including being under 18, pregnancy, breastfeeding, autoimmune disease and hypersensitivity. Ask the clinic to show you the complete list as printed on the packaging insert and confirm, item by item, whether any of it applies to you before treatment.
Sources: FILLMED Laboratoires — NCTF product page, composition, certification and contraindications
How is the product delivered into the skin?
NCTF is injected into the skin using the small, multiple-injection technique generally described as mesotherapy. This site covers the safety questions specific to mesotherapy-style injection in more depth elsewhere; they are not repeated on this page so it can stay focused on what is specific to this product and its one identified trial.
What did the one product-specific clinical trial test?
A randomised trial published in Clin Ter (2026) tested NCTF 135HA added to picosecond laser treatment against picosecond laser alone, in people with melasma. It is the only clinical trial identified that tests a specific NCTF product rather than describing the manufacturer’s own composition statements.
Was this a test of NCTF alone, or of a combination treatment?
It was a combination study. Every participant who received NCTF also received picosecond laser treatment in the same arm; the comparison was against laser treatment on its own, not against no treatment. That design measures whether adding NCTF 135HA to a laser protocol changed the outcome — it does not isolate or measure what NCTF 135HA does when used by itself.
Who took part in the trial, and where was it run?
The trial enrolled 31 people with melasma at a single institution in Moscow: 12 assigned to laser alone and 19 to the NCTF-plus-laser combination. A single-centre trial of this size establishes a result for that setting and that population; it is not a large, multi-site sample.
How long did the trial follow patients, and why does that matter?
Follow-up ran for two months after treatment. That window is enough to record early recurrence but not long-term recurrence or duration of effect; the published figures describe what happened within two months, and this page holds no data on what happens afterward.
What did the trial find, and what does it not show?
Melasma recurrence within the two-month follow-up was 5.3% in the combination group against 25% in the laser-alone group, a difference reported as statistically significant (p<0.05). What it does not show: how NCTF 135HA performs without the laser, how the result would look in a larger or multi-site trial, or whether the difference persists beyond two months.
Does this trial’s result apply to concerns other than melasma?
No. The trial enrolled people with melasma and measured melasma recurrence; it says nothing about hydration, texture, or any other concern this product may be offered for. Treat the trial result as evidence about one combination protocol for one condition, not as general evidence for the product.
Why does the exact product specification matter before booking?
The clinical trial on this page tested one specific formulation, NCTF 135HA, not the NCTF name in general. If a clinic offers ‘NCTF’ or ‘NCTF Mesotherapy’, ask for the exact product designation being used and whether it matches the formulation the evidence describes, rather than assuming the name alone tells you which product is in the syringe.
Sources: FILLMED Laboratoires — NCTF product page, composition, certification and contraindicationsClin Ter 2026 — randomised trial of NCTF 135HA combined with a picosecond laser versus laser alone for melasma (n=31)
How long does the effect last?
The one product-specific trial identified for NCTF followed participants for two months after treatment — long enough to record early melasma recurrence, but not long-term recurrence or a duration of effect, and the trial itself states nothing about how long any change lasts once that two-month window closes. Within it, the reported difference (5.3% recurrence in the NCTF-plus-laser group against 25% for laser alone) describes a combination protocol against picosecond laser alone, in people with melasma specifically — it does not describe NCTF used by itself, and it says nothing about hydration, texture or any other concern outside melasma. For any use of this product, what is more likely to affect how a result holds up is the treatment plan (how many sessions, at what interval), whether it is combined with another procedure such as a laser, the treatment area, and individual skin response — the same variables this page already treats as separate from the manufacturer’s composition claims. Ask the clinic what evidence, if any, it is citing for the specific concern you are treating, and how it decides when a repeat session is due.
What should you confirm before agreeing to this treatment?
Confirm the exact product specification, such as whether it is NCTF 135HA. Disclose pregnancy or breastfeeding, autoimmune disease, and any history of hypersensitivity, and check your age against the manufacturer’s stated contraindications. Ask whether the treatment is planned alone or combined with another procedure such as a laser, and if combined, ask exactly what that other procedure is and why it is being added.
Sources: FILLMED Laboratoires — NCTF product page, composition, certification and contraindicationsClin Ter 2026 — randomised trial of NCTF 135HA combined with a picosecond laser versus laser alone for melasma (n=31)
What Does Each Claim About This Treatment Actually Rest On?
These four things are often mentioned in the same breath when this treatment is offered. This table separates what each one actually is on the record from what it does not establish.
| What is stated | What it is on the record | What it does not establish | What to confirm before booking |
|---|---|---|---|
| ‘60 active ingredients’ | A composition disclosure from the manufacturer’s product page | That any individual ingredient, or the combination, has been shown to outperform a simpler formulation | Whether the clinic can show the ingredient list as the manufacturer states it |
| CE marking and MDR certification (2025-02) | Conformity with EU medical device regulation, as stated by the manufacturer | Any specific cosmetic outcome for any specific skin concern | The certification date, and that it applies to the product actually being used |
| NCTF 135HA + picosecond laser trial (melasma, n=31) | The only product-specific clinical trial identified: a combination protocol compared with laser alone, single-centre, 2-month follow-up | What NCTF 135HA does by itself, how it performs for concerns other than melasma, or results beyond two months | Whether the exact product proposed is 135HA and whether a laser is actually part of your plan |
| ‘NCTF Mesotherapy’ as a menu name | A common name for treatment with this manufacturer’s product line, delivered by injection into the skin | Nothing on its own — the name identifies a delivery route and a product line, not an outcome | Which specific product is being used, in writing, before a date is agreed |
These rows are not tiers of the same claim. A composition list, a regulatory conformity mark and a clinical trial answer different questions, and none of the three extends automatically to the others.
Sources: FILLMED Laboratoires — NCTF product page, composition, certification and contraindicationsClin Ter 2026 — randomised trial of NCTF 135HA combined with a picosecond laser versus laser alone for melasma (n=31)
Medical care at Abijou
Care is provided by the medical team at the branch you select. These clinicians lead the three branches linked from this guide; confirm the doctor assigned to your visit with that branch.
Chief MD, Myeongdong
Cheol-su Yoon
I want to be thinking about how the patient feels right up to the last moment of the procedure.
Chief MD, Hongdae
Jae-wook Kim
I will give my best with the attentiveness to catch even the smallest change.
Listed branch medical team — not a medical-review byline for this article.
Frequently asked questions
Is NCTF Mesotherapy one approved treatment or a general treatment category?
It is treatment with one manufacturer’s specific product line, FILLMED Laboratoires’ NCTF, not a general category. What applies to it is what this manufacturer states about this product and what the one identified clinical trial tested — not general mesotherapy or skin-booster evidence covered elsewhere on this site.
Who makes NCTF, and has the brand name changed?
FILLMED Laboratoires manufactures it, and the company describes this as formerly Filorga’s professional-use line. The NCTF formulation itself was developed in 1978, so ask the clinic to confirm the manufacturer name printed on the product you are shown.
What does ‘60 active ingredients’ mean on the product page?
It means the manufacturer discloses a combination formulation of 60 ingredients, including vitamins, amino acids, minerals and hyaluronic acid. It is a list of composition, not a claim that each ingredient’s individual effect has been proven.
Does a 60-ingredient formulation work better than a single-ingredient product?
No source on this page compares the two. A long ingredient list tells you the formulation is complex, not that the combination has been shown to outperform a simpler product, so that comparison is not something this page can support.
What does the CE marking and MDR certification actually certify?
It certifies conformity with EU medical device regulation — manufacturing, quality and safety requirements — dated 2025-02 according to the manufacturer. It does not certify any specific cosmetic outcome for melasma, hydration or any other concern.
Who should not receive this treatment, according to the manufacturer?
The manufacturer lists people under 18, pregnant or breastfeeding people, people with autoimmune disease, and people with hypersensitivity. Disclose each of these at consultation and ask to see the complete list as printed on the packaging insert.
Was NCTF 135HA tested by itself, or together with something else?
Together with a picosecond laser. The identified trial compared NCTF 135HA plus laser against laser alone, so its result describes what adding NCTF did to a laser protocol, not what NCTF does on its own.
Who took part in the melasma trial, and how large was it?
31 people with melasma at a single institution in Moscow — 12 in the laser-alone group and 19 in the NCTF-plus-laser group. That is a single-centre trial of modest size, not a large multi-site sample.
How long did the trial follow patients, and what does that limit?
Two months. That is long enough to record early recurrence but says nothing about recurrence or effect beyond that window, so treat the published figures as a two-month result rather than a long-term one.
What did the trial find about recurrence, and what does it not prove?
Melasma recurrence within two months was 5.3% in the combination group against 25% in the laser-alone group, reported as statistically significant. It does not prove how NCTF 135HA performs without the laser, in a larger trial, or beyond two months.
Can these melasma results be applied to other skin concerns?
No. The trial measured melasma recurrence after one specific combination protocol; it holds no data on hydration, texture or any other concern this product may be offered for, so extending the result beyond melasma is not something the trial supports.
How is NCTF delivered, and where can I read about general injection safety questions?
It is delivered by injection into the skin using the small-injection technique generally described as mesotherapy. This site’s broader coverage of mesotherapy-style injection safety applies to the delivery method in general and is not repeated on this page.
What should I ask about the exact product before booking?
Ask for the exact product designation, such as whether it is NCTF 135HA, because the clinical trial on this page applies to that specific formulation and not to the NCTF name in general. A menu name alone does not tell you which product is in the syringe.
What should I disclose at consultation before this treatment?
Disclose pregnancy or breastfeeding, autoimmune disease, any history of hypersensitivity, and your age. Also ask whether the treatment is planned alone or combined with another procedure such as a laser, and if combined, what exactly that other procedure is.
How Abijou works
We started in Gangnam in 2006 and the network now runs 17 branches across Korea. The line we work to is skin transformation woven into everyday life — care you can keep up with, rather than one dramatic change.
- Across the 17 branches in Seoul, Gyeonggi, Incheon and Busan: over 1,000 medical professionals and more than 350 certified medical devices
- Authentic products only, in appropriate amounts — the treatment is fitted to the condition, not to a package
- Prices are quoted from each branch’s published price list as it stands
Contact and location
- Phone
- 1544-0377
Free Consultation
Booking happens at the branch
There is no inquiry form on this page. Once you have picked a branch above, open that branch’s site or the official reservation center and choose a time yourself.
- No deposit and no online prepayment — everything is paid at the visit
- Per-treatment prices are published for each branch on the official reservation center
- English, Japanese and Chinese are supported alongside Korean